双重 GIP 和 GLP-1 受体激动剂--替扎帕肽在减肥管理中的作用；系统性综述。

IF 0.7 Q4 PHARMACOLOGY & PHARMACY Current drug safety Pub Date : 2024-10-31 DOI:10.2174/0115748863330434241015125302

Imran Rashid Rangraze, Shehla Khan, Adil Farooq Wali, Godfred Menezes, Manjunatha Goud, Muhammad Jabran

{"title":"双重 GIP 和 GLP-1 受体激动剂--替扎帕肽在减肥管理中的作用；系统性综述。","authors":"Imran Rashid Rangraze, Shehla Khan, Adil Farooq Wali, Godfred Menezes, Manjunatha Goud, Muhammad Jabran","doi":"10.2174/0115748863330434241015125302","DOIUrl":null,"url":null,"abstract":"Introduction: Tirzepatide, a dual GIP and GLP-1 receptor agonist, is a promising therapeutic option for obesity and metabolic disorders.Methods: Systematic review following PRISMA guidelines across PubMed, Embase, and Cochrane. Included RCTs and observational studies.Results: Seven phase 3 trials showed significant, dose-dependent reductions in body weight and improvements in metabolic markers. Well-tolerated, with low rates of hypoglycemia. Subgroups with higher BMI had greater benefits.Discussion: Demonstrates consistent efficacy and safety across diverse populations; personalized approaches may optimize outcomes.Conclusion: Tirzepatide is effective, safe, and durable in managing obesity and metabolic disorders; long-term studies warranted.","PeriodicalId":10777,"journal":{"name":"Current drug safety","volume":" ","pages":""},"PeriodicalIF":0.7000,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Role of Dual GIP and GLP-1 Receptor Agonist, Tirzepatide in the Management of Weight Loss; A Systematic Review\",\"authors\":\"Imran Rashid Rangraze, Shehla Khan, Adil Farooq Wali, Godfred Menezes, Manjunatha Goud, Muhammad Jabran\",\"doi\":\"10.2174/0115748863330434241015125302\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Introduction: Tirzepatide, a dual GIP and GLP-1 receptor agonist, is a promising therapeutic option for obesity and metabolic disorders.Methods: Systematic review following PRISMA guidelines across PubMed, Embase, and Cochrane. Included RCTs and observational studies.Results: Seven phase 3 trials showed significant, dose-dependent reductions in body weight and improvements in metabolic markers. Well-tolerated, with low rates of hypoglycemia. Subgroups with higher BMI had greater benefits.Discussion: Demonstrates consistent efficacy and safety across diverse populations; personalized approaches may optimize outcomes.Conclusion: Tirzepatide is effective, safe, and durable in managing obesity and metabolic disorders; long-term studies warranted.\",\"PeriodicalId\":10777,\"journal\":{\"name\":\"Current drug safety\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.7000,\"publicationDate\":\"2024-10-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current drug safety\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/0115748863330434241015125302\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current drug safety","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0115748863330434241015125302","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

摘要

目的：本综述探讨了替哌肽作为一种二元GIP和GLP- 1受体激动剂治疗肥胖症和代谢性疾病的可能性：背景：对替泽帕肽的定义是，鉴于其疗效依赖性，它是一种隐性的肥胖症干预措施。除了对体重减轻有益外，替扎帕肽还能改善血脂和胰岛素敏感性，并与二元受体激活相协调：方法：通过对七项第三阶段试验的数据进行分析，结果表明替瑞沙肽能显著减轻体重，而且对不同的人群和不同的时间长度都有临床意义：结果：该药物的效果得到了其良好安全性的支持，其常见不良反应发生率较低。它在治疗 2 型糖尿病方面的疗效得到了相对评价的支持，这凸显了它作为一种治疗手段取得突破的必然性。治疗的个体化是关键，基于出生体重指数的分组分析所提出的量身定制的对策就是证明。结论：结论：通过长期随访研究证实，替扎帕肽可作为治疗习惯性肥胖的长期策略，并可持续减轻体重。尽管取得了这些令人鼓舞的结果，但仍需要进一步的研究和临床经验，以全面了解替扎帕肽在不同患者群体中的安全性、最佳整合性和长期有效性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Role of Dual GIP and GLP-1 Receptor Agonist, Tirzepatide in the Management of Weight Loss; A Systematic Review

Introduction: Tirzepatide, a dual GIP and GLP-1 receptor agonist, is a promising therapeutic option for obesity and metabolic disorders.

Methods: Systematic review following PRISMA guidelines across PubMed, Embase, and Cochrane. Included RCTs and observational studies.

Results: Seven phase 3 trials showed significant, dose-dependent reductions in body weight and improvements in metabolic markers. Well-tolerated, with low rates of hypoglycemia. Subgroups with higher BMI had greater benefits.

Discussion: Demonstrates consistent efficacy and safety across diverse populations; personalized approaches may optimize outcomes.

Conclusion: Tirzepatide is effective, safe, and durable in managing obesity and metabolic disorders; long-term studies warranted.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Current drug safety PHARMACOLOGY & PHARMACY-

CiteScore

2.10

自引率

0.00%

发文量

112

期刊介绍： Current Drug Safety publishes frontier articles on all the latest advances on drug safety. The journal aims to publish the highest quality research articles, reviews and case reports in the field. Topics covered include: adverse effects of individual drugs and drug classes, management of adverse effects, pharmacovigilance and pharmacoepidemiology of new and existing drugs, post-marketing surveillance. The journal is essential reading for all researchers and clinicians involved in drug safety.